Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3493-3499

  Li, Yang ^a   Schmidt Wolf, Ingo G H ^b   Wu, Yan Feng ^a   Huang, Shao Liang ^a   Wei, Jing ^a   Fang, Jianpei ^a   Huang, Ke ^a   Zhou, Dun Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cytokine induced killer cell; Immunotherapy; Interleukin

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CYTOKINE; FLT3 LIGAND; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; STEM CELL FACTOR; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN;

ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CLINICAL PROTOCOL; CYTOTOXICITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; UMBILICAL CORD BLOOD; CULTURE TECHNIQUE; CYTOKINE INDUCED KILLER CELL; CYTOLOGY; FETUS BLOOD; IMMUNOLOGY; PROCEDURES;

CELL CULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FETAL BLOOD; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; STEM CELL FACTOR;

EID: 77958581448     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21: 1673-1679, 1993.
2. Nagaraj S, Ziske C and Schmidt-Wolf IG: Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Ther 2: 12-18, 2004.
3. Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A and Rambaldi A: Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Hematol 92: 952-959, 2007.
4. Shiver JW, Su L and Henkart PA: Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A. Cell 71: 315-322, 1992.
5. (+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92: 3318-3327, 1998.
6. Leemhuis T, Wells S, Scheffold C, Edinger M and Negrin RS: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11: 181-187, 2005. (Pubitemid 40287916)
7. Scheffold C, Brandt K, Johnston V and Lefterova P, Degen B, Schöntube M, Huhn D, Neubauer A and Schmidt-Wolf IG: Potential of autologus immunolgic effector cell for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 15: 33-39, 1995.
8. Shi-Xia X, Xian-Hua T and Xiang-Feng T: Unrelated umbilical cord blood transplantation and unrelated bone marrow transplantation in children with hematological disease: A meta-analysis. Pediatr Transplant 13: 278-284, 2009.
9. Wu T and Lu DP: Blood and marrow transplantation in the People's Republic of China. Bone Marrow Transplant 42(Suppl 1): 73-75, 2008.
10. Locatelli F, Giorgiani G, Di-Cesare-Merlone A, Merli P, Sparta V and Moretta F: The changing role of stem cell transplantation in childhood. Bone Marrow Transplant 41(Suppl 2): 3-7, 2008.
11. Gluckman E and Rocha V: Indications and results of cord blood transplant in children with leukemia. Bone Marrow Transplant 41(Suppl 2): 80-82, 2008.
12. Harris DT: In vitro and in vivo assessment of the graft-versus-l eukemia activity of cord blood. Bone Marrow Transplant 15: 17-23, 1995.
13. + cells derived from T-cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696, 1994.
14. YU JP, Ren XB, Zhang P, An XM, Zhang NN and Hao XS: Large-capacity expanded in vitro and biological characteristics assay of cytokine induced killer cells in malignant solid tumors patients. Chin J Cancer Biother 8: 215-216, 2001.
15. Xu K, Li C, Pan X and Du B: Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand co-stimulatory pathway in vitro. Int J Hematol 86: 84-90, 2007.
16. Abrahamsen IW, Sømme S, Heldal D, Egeland T, Kvale D and Tjønnfjord GE: Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica 90: 86-93, 2005.
17. Meshulam T, Levitz SM, Christin L and Diamond RD: A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide (XTT). J Infect Dis 172: 1153-1156, 1995.
18. + killer cells. Blood 86: 3493-3499, 1995.
19. Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J and Rambaldi A: Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 38: 621-627, 2006.
20. + NK T- and gamma delta T-cells from cord blood of human neonates. Clin Exp Immunol 113: 220-228, 1998.
21. Lanier LL, Le AM, Civin CI, Loken MR and Phillips JH: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136: 4480-4486, 1986.
22. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
23. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG and Negrin RS: Propagation of large numbers of T-cells with natural killer cell markers. Br J Haematol 87: 453-458, 1994.
24. Ren H, Xu HW, Song YH, Li HL, Zhong ZH, Xing SX, Tian JX: The proliferation of CIK cells and its cytotoxicity on tumor cells in vitro. Chin J of Immunol 14: 406-408, 1998.
25. Kang ZZ, Cai HB, Xu L and Tan WS: Study on influence of different cultural conditions on CIK cells purity. Immunological J 17: 385-387, 2001.
26. Wendel M, Galani IE, Suri-Payer E and Cerwenka A: Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68: 8437-8445, 2008.
27. Hallett WH, Ames E, Alvarez M, Barao I, Taylor PA, Blazar BR and Murphy WJ: Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant 14: 1088-1099, 2008.
28. - CD56 bright natural killer cells mediated by increased expression of the IL-2 receptor alpha chain. J Reprod Immunol 40: 1-24, 1998.
29. Skovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD and Peschon JJ: Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95: 3489-3497, 2000.
30. (+) human natural killer cell progenitor that responds to interleukin-15. Blood 92: 3647-3657, 1998.
31. Matsumura N, Mandai M, Hamanishi J, Yamaguchi K, Fukuhara K, Yagi H, Higuchi T, Takakura K and Fujii S: Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment. Oncol Rep 19: 505-515, 2008.
32. + immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther 5: 31-39, 1998.
33. Miller JS, Tessmer-Tuck J, Blake N, Lund J, Scott A, Blazar BR and Orchard PJ: Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer. Exp Hematol 25: 1140-1148, 1997. (Pubitemid 27444675)
34. Mingari MC, Vitale C, Cantoni C, Bellomo R, Ponte M, Schiavetti F, Bertone S, Moretta A and Moretta L: Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur J Immunol 27: 1374-1380, 1997.
35. Braun S, Gerhartz HH and Schmetzer HM: Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro. Haematologia 30: 271-288, 2000.
36. Favre-Felix N, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E, Martin F and Bonnotte B: Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. J Cancer 86: 827-834, 2000.